[68Ga]NODAGA-RGD – Metabolic stability, biodistribution, and dosimetry data from patients with hepatocellular carcinoma and liver cirrhosis

• DOI: 10.1007/s00259-016-3396-3
• Publication Date: 2016-05-11T01:21:31Z
• Authors: Roland Haubner; Armin Finkenstedt; Armin Stegmayr; Christine Rangger; Clemens Decristoforo; Heinz Zoller; Irene J. Virgolini
• Keywords: Biodistribution

This study was designed to determine safety, tolerability, and radiation burden of a [68Ga]NODAGA-RGD-PET for imaging integrin αvβ3 expression in patients with hepatocellular carcinoma (HCC) liver cirrhosis. Moreover, metabolic stability biokinetic data were compiled. After injection 154–184 MBq [68Ga]NODAGA-RGD three consecutive PET/CT scans acquired starting 8.3 ± 2.1, 36.9 2.8, 75.1 3.4 min after tracer injection. For metabolite analysis, blood urine samples analyzed by HPLC. dosimetry studies, residence time VOIs placed the corresponding organs. The OLINDA/EXM program used estimate absorbed dose. radiopharmaceutical well tolerated no drug-related adverse effects observed. No metabolites could be detected (30 60 p.i.) (60 p.i.). showed rapid predominantly renal elimination. Background radioactivity blood, intestine, lung, muscle tissue low (%ID/l p.i. 0.56 0.43, 0.54 0.39, 0.22 0.05, 0.16 0.8, respectively). calculated effective dose 21.5 5.4 μSv/MBq, highest found urinary bladder wall (0.26 0.09 mSv/MBq). increased uptake HCC compared background tissue. HCCs lesions not sufficient use this these tumors. metabolically stable. Due excretion, most body, resulting indicating potential PET non-invasive determination expression.